Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 6/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 6/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 6/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rezatomidine SCHEMBL345466 | 1.00 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Rezatomidine SCHEMBL29376551 | 1.00 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Rezatomidine SCHEMBL676215 | 1.00 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL14546567 | 0.84 | ADRA2A (0.38) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL8510869 | 0.81 | GABRA1 (0.37) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL8510363 | 0.81 | GABRA1 (0.37) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL3709658 | 0.81 | GABRA1 (0.37) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL3749391 | 0.78 | ADRA2A (0.55) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL3418059 | 0.78 | CYP1A2 (0.45) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL3419587 | 0.78 | CES2 (0.33) | ADRA2AADRA2BADRA2CADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2124912-B1 | ALPHA-2B ADRENERGIC RECEPTOR AGONIST AND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN INC (US) | 2014-12-03 | — | — | EP | disclosed |
| WO-2013074320-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| US-20120190719-A1 | METHODS OF TREATING MOTOR DISORDERS WITH ALPHA-2B ANDRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120083508-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-20110269805-A1 | METHOD OF TREATING SENSORIMOTOR DISORDERS WITH 4-(1-(2,3-DIMETHYLPHENYL)ETHYL)-1H-IMIDAZOLE-2(3H)-THIONE | GIL DANIEL W | 2011-11-03 | — | — | US | disclosed |
| US-20100216857-A1 | METHOD OF TREATING MOTOR DISORDERS WITH 4-(1-(2,3-DIMETHYLPHENYL)ETHYL)-1H-IMIDAZOLE-2(3H)-THIONE | LUHRS LAUREN M B | 2010-08-26 | — | — | US | disclosed |
| US-20100216857-A1 | METHOD OF TREATING MOTOR DISORDERS WITH 4-(1-(2,3-DIMETHYLPHENYL)ETHYL)-1H-IMIDAZOLE-2(3H)-THIONE | LUHRS LAUREN M B | 2010-08-26 | — | — | US | disclosed |
| US-20100016355-A1 | ALPHA-2B ADRENERGIC RECEPTOR AGONIST AND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR COMPOSITIONS FOR TREATING CHRONIC PAIN | GIL DANIEL W | 2010-01-21 | — | — | US | disclosed |
| US-20090252802-A1 | Compositions Including Relatively Water Insoluble/Unwettable Drugs And Methods For Using Same | ALLERGAN, INC. | 2009-10-08 | — | — | US | disclosed |
| US-20090252802-A1 | Compositions Including Relatively Water Insoluble/Unwettable Drugs And Methods For Using Same | ALLERGAN, INC. | 2009-10-08 | — | — | US | disclosed |
| US-20080153825-A1 | ALPHA-2B RECEPTOR AGONIST AND 5HT4 SEROTONIN RECEPTOR COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | ALLERGAN INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153825-A1 | ALPHA-2B RECEPTOR AGONIST AND 5HT4 SEROTONIN RECEPTOR COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | ALLERGAN INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153927-A1 | ALPHA-2B RECEPTOR AGONIST AND RELAXANT COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | ALLERGAN, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153927-A1 | ALPHA-2B RECEPTOR AGONIST AND RELAXANT COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | ALLERGAN, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153874-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153881-A1 | ALPHA-2B RECEPTOR AGONIST AND ACID REDUCER COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | ALLERGAN, INC. | 2008-06-26 | — | — | US | disclosed |
| WO-2008014299-A2 | USE OF AN ALPHA2-AGONIST COMPOSITION FOR THE TREATMENT OF HYPERLIPIDEMIA | ALLERGAN, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2007117923-A2 | COMPOSITIONS INCLUDING RELATIVELY WATER INSOLUBLE/UNWETTABLE DRUGS AND METHODS FOR USING SAME | ALLERGAN, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20070203144-A1 | Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals | ALLERGAN, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203144-A1 | Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals | ALLERGAN, INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203144-A1 | Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals | KDR, MTNR1B, VEGFA | ADRA2A 82/4885ADRA2B 18/4885ADRA2C 194/4885 |
| US-20100216857-A1 | METHOD OF TREATING MOTOR DISORDERS WITH 4-(1-(2,3-DIMETHYLPHENYL)ETHYL)-1H-IMIDAZOLE-2(3H)-THIONE | SMN1; SMN2, ACHE, MTPN | ADRA2A 1549/4885ADRA2B 1863/4885ADRA2C 1131/4885 |
| US-20100016355-A1 | ALPHA-2B ADRENERGIC RECEPTOR AGONIST AND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR COMPOSITIONS FOR TREATING CHRONIC PAIN | ADRA2B, ADRA1B, ADRB1 | ADRA2A 6/4885ADRA2B 1/4885ADRA2C 4/4885 |
| US-20090252802-A1 | Compositions Including Relatively Water Insoluble/Unwettable Drugs And Methods For Using Same | LIPA, SGMS2, SGMS1 | ADRA2A 2487/4885ADRA2B 2646/4885ADRA2C 1638/4885 |
| US-20080153881-A1 | ALPHA-2B RECEPTOR AGONIST AND ACID REDUCER COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | ADRA2B, GPBAR1, MLNR | ADRA2A 8/4885ADRA2B 1/4885ADRA2C 16/4885 |
| US-20120083508-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | CNR2, OPRL1, OPRD1 | ADRA2A 39/4885ADRA2B 6/4885ADRA2C 44/4885 |
| US-20110269805-A1 | METHOD OF TREATING SENSORIMOTOR DISORDERS WITH 4-(1-(2,3-DIMETHYLPHENYL)ETHYL)-1H-IMIDAZOLE-2(3H)-THIONE | PMP22, SMN1; SMN2, TST | ADRA2A 1268/4885ADRA2B 1512/4885ADRA2C 1261/4885 |
| US-20080153927-A1 | ALPHA-2B RECEPTOR AGONIST AND RELAXANT COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | ADRA2B, ADRA1B, CCKBR | ADRA2A 5/4885ADRA2B 1/4885ADRA2C 7/4885 |
| US-20080153825-A1 | ALPHA-2B RECEPTOR AGONIST AND 5HT4 SEROTONIN RECEPTOR COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | HTR2B, HTR4, HTR3B | ADRA2A 26/4885ADRA2B 12/4885ADRA2C 23/4885 |
| US-20080153874-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | CNR2, OPRL1, OPRD1 | ADRA2A 39/4885ADRA2B 6/4885ADRA2C 44/4885 |
| US-20120190719-A1 | METHODS OF TREATING MOTOR DISORDERS WITH ALPHA-2B ANDRENERGIC RECEPTOR AGONISTS | CHRNB2, HTR2B, CHRNA2 | ADRA2A 22/4885ADRA2B 20/4885ADRA2C 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.